Transdermal Delivery Solutions and MHC Medical Products announce license for Penetran+Plus topical pain reliever
With the acquisition of Penetran-Plus, MHC expands into the OTC pain relief market.
Transdermal Delivery Solutions Corporation (TDSC), a developer of spray-on drug delivery systems, has signed a product license arrangement with MHC Medical Products, of Cincinnati, OH — a rapidly growing consumer healthcare company.
"We are pleased to announce the finalization of our agreement for this first product with the team at MHC,” said Kenneth Kirby, President of TDSC. “MHC is the manufacturer of one of the country’s fastest growing lines of branded medical devices and other consumer healthcare products including the EasyTouch brand of insulin syringes and blood glucose meters, HealthPro blood glucose meters, and SureLife blood pressure monitors.” With the acquisition of Penetran-Plus, MHC is expanding into the over-the-counter pain relief market.
Up until this time, Penetran+Plus had limited regional distribution. “We are pleased and honored to have the MHC team acquire the product license and expand the distribution,” said Kirby. Penetran+Plus is a topical analgesic gel that is marketed as an over-the-counter remedy for temporary relief of minor aches and pains, bruises and strains. The product was designed with a pleasant natural lemon oil fragrance, a non-sticky formula and has been successfully tested for pains associated with arthritis in a double blind study against placebo which was published in a peer-reviewed journal. The product label has been reviewed by the FDA Center for Drug Evaluation and Research Office of Unapproved Drugs and Labeling Compliance (OUDLC), Over the Counter Branch and found to be in compliance with the OTC Monograph for Topical Pain Relief.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.